$33.22
0.65% yesterday
Nasdaq, Nov 15, 10:00 pm CET
ISIN
US4131971040
Symbol
HRMY

Harmony Biosciences Holdings Stock News

Positive
Seeking Alpha
4 days ago
Harmony Biosciences Holdings, Inc.'s potential expansion of WAKIX targeting patients with idiopathic hypersomnia possible with filing of sNDA expected in Q4 of 2024. Net sales of Wakix in Q3 of 2024 reached $186 million. The company surpassed $2 billion in cumulative net product revenue less than 5 years on the market, highlighting rapid growth.
Neutral
PRNewsWire
16 days ago
PLYMOUTH MEETING, Pa. , Oct. 30, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) (the "Company") today announced the pricing of the previously announced underwritten public offering of an aggregate of 8,000,000 shares of the Company's common stock, par value $0.00001 per share ("Common Stock"), by Marshman Fund Trust II and Valor IV Pharma Holdings, LLC (together, the "Se...
Neutral
PRNewsWire
17 days ago
PLYMOUTH MEETING, Pa. , Oct. 29, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) (the "Company") today announced the commencement of an underwritten public offering of up to 8,000,000 shares of the Company's common stock, par value $0.00001 per share ("Common Stock"), by Marshman Fund Trust II and Valor IV Pharma Holdings, LLC (together, the "Selling Shareholders").
Neutral
Seeking Alpha
17 days ago
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY ) Q3 2024 Earnings Conference Call October 29, 2024 8:30 AM ET Company Participants Brennan Doyle - Head of Investor Relations Jeffrey Dayno - President & Chief Executive Officer Jeffrey Dierks - Chief Commercial Officer Kumar Budur - Chief Medical Officer & Scientific Officer Sandip Kapadia - Chief Financial Officer & Chief Administrative Officer...
Positive
Investors Business Daily
18 days ago
Harmony Biosciences stock jumped Tuesday on the biotech company's "high-quality" third-quarter beat on the back of its narcolepsy drug.
Neutral
PRNewsWire
about one month ago
PLYMOUTH MEETING, Pa. , Oct. 16, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report third quarter 2024 financial results on Tuesday, October 29, 2024, before the open of the U.S. financial markets.
Neutral
PRNewsWire
about 2 months ago
PLYMOUTH MEETING, Pa. , Oct. 1, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), will be providing a comprehensive pipeline update at its Investor Day event today, showcasing new data from its orexin-2 receptor agonist, next-generation pitolisant programs, and long-term extension data from its pitolisant program in idiopathic hypersomnia.
Neutral
PRNewsWire
about 2 months ago
PLYMOUTH MEETING, Pa. , Sept. 26, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), will provide an overview of its robust, late-stage pipeline at an in-person Investor Day at 8:30 a.m.

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today